US Stock Market Move | Data center operator Csquare (CSQR.US) launches on the US stock market, with the stock price dropping over 1% after opening.
As of press time, the stock has fallen more than 1%, trading at $20.77.
On Thursday, Csqaure (CSQR.US) debuted on the US stock market. As of the time of writing, the stock has dropped by over 1% to $20.77. The IPO price was $21. Csqaure is a carrier-neutral colocation data center operator that provides space, power resources, and core connectivity infrastructure for enterprises, network service providers, and large cloud computing platforms to house and operate their high-performance IT equipment. As of March 31, 2026, the company operates 64 large infrastructures in 21 major metropolitan markets in the United States, offering services including enterprise colocation, compute interconnection services, and other colocation cloud infrastructure solutions. Its facilities are designed to support long-cycle, highly availability-sensitive workloads, with a single-rack power density of up to 150 kilowatts. The company's revenue is mainly derived from recurring contracts for colocation and compute interconnection services, with cloud computing/data center interconnection related services accounting for approximately 10% to 13% of recurring revenue in recent years.
Related Articles

Price starting at 12,380 yuan, Xiaopeng (09868) MONA L03 will be globally launched, setting a new benchmark for native global vehicle models.

GMTEight List of A-share restricted sales and lifting restrictions | July 17th

Shanghai Fosun Pharmaceutical (02196) innovative small nucleic acid drug FXR0906 has been approved for clinical trial "30-day fast track" for the treatment of hypertriglyceridemia.
Price starting at 12,380 yuan, Xiaopeng (09868) MONA L03 will be globally launched, setting a new benchmark for native global vehicle models.

GMTEight List of A-share restricted sales and lifting restrictions | July 17th

Shanghai Fosun Pharmaceutical (02196) innovative small nucleic acid drug FXR0906 has been approved for clinical trial "30-day fast track" for the treatment of hypertriglyceridemia.

RECOMMEND





